561 related articles for article (PubMed ID: 34021585)
1. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
[TBL] [Abstract][Full Text] [Related]
2. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison.
Mahon R; Tiwari S; Koch M; Ferraris M; Betts KA; Wang Y; Gao S; Proot P
J Comp Eff Res; 2024 Mar; 13(3):e230122. PubMed ID: 38174577
[No Abstract] [Full Text] [Related]
4. Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305).
Powell LC; L'Italien G; Popoff E; Johnston K; O'Sullivan F; Harris L; Croop R; Coric V; Lipton RB
Adv Ther; 2023 Feb; 40(2):585-600. PubMed ID: 36417057
[TBL] [Abstract][Full Text] [Related]
5. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
[TBL] [Abstract][Full Text] [Related]
6. Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant.
Johnston KM; L'Italien G; Popoff E; Powell L; Croop R; Thiry A; Harris L; Coric V; Lipton RB
Adv Ther; 2021 Oct; 38(10):5209-5220. PubMed ID: 34455556
[TBL] [Abstract][Full Text] [Related]
7. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201).
Johnston K; Harris L; Powell L; Popoff E; Coric V; L'Italien G; Schreiber CP
J Headache Pain; 2022 Jan; 23(1):10. PubMed ID: 35038983
[TBL] [Abstract][Full Text] [Related]
8. Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial.
Schwedt TJ; Myers Oakes TM; Martinez JM; Vargas BB; Pandey H; Pearlman EM; Richardson DR; Varnado OJ; Cobas Meyer M; Goadsby PJ
Neurol Ther; 2024 Feb; 13(1):85-105. PubMed ID: 37948006
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
[TBL] [Abstract][Full Text] [Related]
10. Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability.
Ford JH; Ayer DW; Zhang Q; Carter JN; Leroux E; Skljarevski V; Aurora SK; Tockhorn-Heidenreich A; Lipton RB
Neurology; 2019 Jul; 93(5):e508-e517. PubMed ID: 31270220
[TBL] [Abstract][Full Text] [Related]
11. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
Mullin K; Kudrow D; Croop R; Lovegren M; Conway CM; Coric V; Lipton RB
Neurology; 2020 May; 94(20):e2121-e2125. PubMed ID: 31932515
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
Tassorelli C; Onishchenko K; Halker Singh RB; Duan M; Dupont-Benjamin L; Hemstock M; Voller C; McAllister P; Nahas SJ; Gandhi P; Ailani J
Cephalalgia; 2024 Feb; 44(2):3331024241235156. PubMed ID: 38410850
[TBL] [Abstract][Full Text] [Related]
13. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
Croop R; Lipton RB; Kudrow D; Stock DA; Kamen L; Conway CM; Stock EG; Coric V; Goadsby PJ
Lancet; 2021 Jan; 397(10268):51-60. PubMed ID: 33338437
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
16. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN).
Ford J; Tassorelli C; Leroux E; Wang S; Ayer D; Nichols R; Detke H
Qual Life Res; 2021 Jan; 30(1):105-115. PubMed ID: 32930994
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
18. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
[TBL] [Abstract][Full Text] [Related]
19. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
[TBL] [Abstract][Full Text] [Related]
20. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
